Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Malcolm J. Moore, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Jeremy K. Hon, Mikhail Yu Biakhov, Sunil R. Hingorani, Vinod Ganju, Colin D. Weekes, Werner Scheithauer, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Xinyu Wei, Alfredo Romano
Institutions: Princess Margaret Cancer Centre, Translational Genomics Research Institute, Florida Cancer Specialists & Research Institute, University of Washington, Tennessee Oncology, Clearview Cancer Institute, Central Clinical Hospital No 2 named Semashko, Fred Hutch Cancer Center, Peninsula Health, University of Colorado Cancer Center, Medical University of Vienna, Vall d'Hebron Hospital Universitari, Prince of Wales Hospital, Celgene (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2586892955
